Abstract
Numerous case reports of pregnancy in acromegaly exist, however detailed descriptions of changes in placental and pituitary GH and IGF-I throughout gestation are rare. A 19-yr-old female presented to this institution with signs and symptoms of a GH-secreting pituitary adenoma. Following transphenoidal hypophysectomy, she had 3 unplanned pregnancies, despite ongoing active disease. No pregnancy was complicated by glucose intolerance or hypertension and 3 healthy newborns were delivered near or at term. Clinical improvement was observed during each pregnancy, accompanied by IGF-I levels lower than in the non-pregnant state, the majority lying within the normal range. This was despite increasing placental GH levels, and was not consistent with previous reports in the literature. Further surgical and medical therapies for acromegaly failed to normalize non-pregnant GH or IGF-I levels in this woman. Estrogen is known to alter GH signaling via its interaction with Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathways. We hypothesize that increasing concentrations of estrogen or other pregnancy-related hormones resulted in her clinical and biochemical improvement during pregnancy. This may be used for future therapeutic benefit.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
de Menis E, Billeci D, Marton E. Uneventful pregnancy in an acromegalic patient treated with slow-release lanreotide: a case report. J Clin Endocrinol Metab 1999, 84: 1489.
Takeuchi K, Funakoshi T, Oomori S, Maruo T. Successful pregnancy in an acromegalic woman treated with octreotide. Obstet Gynecol 1999, 93: 848.
Bronstein MD, Salgado LR, de Castro Muslino NR. Medical management of pituitary adenoma: the special case of management of the pregnant woman. Pituitary 2002, 5: 99–107.
Herman-Bonert V, Seliverstov M, Melmed S. Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 1998, 83: 727–31.
Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997, 82: 2777–81.
Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F. Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 1990, 71: 725–31.
Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 2001, 55: 411–5.
Landolt AM, Schmid J, Wimpfheimer C, Karlsson ER, Boerlin V. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. N Engl J Med 320: 671–2.
Hierl T, Ziegler R, Kasperk C. Pregnancy in persistent acromegaly. Clin Endocrinol (Oxf) 2000, 53: 262–3.
Mikhail N. Octreotide treatment of acromegaly during pregnancy. Mayo Clinic Proc 2002, 77: 297–8.
Eriksson L, Frankenne F, Edèn S, Hennen G, Von Schoultz B. Growth hormone 24-h serum profiles during pregnancy — lack of pulsatility for the secretion of the placental variant. BrJ Obstet Gynaecol 1989, 96: 949–53.
Lønberg U, Damm P, Andersson A, et al. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. Am J Obstet Gynecol 2003, 188: 247–51.
Frankenne F, Closset J, Gomez F, Scippo M, Smal J, Hennen G. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 1988, 66: 1171–80.
Chellakooty M, Vangsgaard K, Larsen T, et al. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 2004, 89: 384–91.
Verhaeghe J, Bougoussa M, Van Herck E, de Zegher F, Hennen G, Igout A. Placental growth hormone and IGF-1 in a pregnant woman with Pit-1 deficiency. Clin Endocrinol 2000, 53: 645–7.
Okada Y, Morimoto I, Ejima K, et al. A case of active acromegalic woman with a marked increase in serum insulin-like growth factor-1 levels after delivery. Endocr J 1997, 44: 117–20.
Obuobie K, Mullik V, Jones C, et al. McCune-Albright syndrome: growth hormone dynamics in pregnancy. J Clin Endocrinol Metab 2001, 86: 2456–8.
Leung KC, Johannsson G, Leong G, Ho KKY. Estrogen regulation of growth hormone action. Endocr Rev 2004, 25: 693–721.
Suikkari A-M, Baxter RC. Insulin-like growth factor binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab 1992, 74: 177–83.
Lacroix MC, Guibourdenche J, Fournier T, et al. Stimulation of human trophoblast invasion by placental growth-hormone. Endocrinology 2005, 146: 2434–44.
van den Berg G, Veldhuis JD, Frölich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996, 81: 2460–7.
Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987, 64: 51–8.
Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991, 72: 374–81.
Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 1996, 81: 2250–6.
Leung KC, Ho KKY. Stimulation of mitochondrial fatty acid oxidation by growth hormone in human fibroblasts. J Clin Endocrinol Metab 1997, 82: 4208–13.
Parkinson C, Ryder WD, Trainer P; Sensus Acromegaly Study Group. The relationship between serum GH and Serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 2001, 86: 5240–4.
Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 1980, 69: 571–5.
Nugent A, Gibney J, Johannsson G, Ng WYW, Leung KC, Ho KKY. Treatment of acromegaly with oral estrogen. Program of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, 2003, p285 (Abstract P1-638).
Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R. Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 2003, 26: 347–52.
Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KKY. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin endocrinol (Oxf) 2003, 59: 690–8.
Imon S, Schiffer M, Glick S, Schwartz E. Effect of medroxyprogesterone acetate upon stimulated release of growth hormone in men. J Clin Endocrinol Metab 1967, 27: 1633–6.
Lawrence A, Kirsteins L. Progestins in the medical management of active acromegaly. J Clin Endocrinol Metab 1970, 30: 646–52.
Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 levels and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995, 42: 417–23.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lau, S.L., McGrath, S., Evain-Brion, D. et al. Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31, 255–261 (2008). https://doi.org/10.1007/BF03345599
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345599